PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933376
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933376
The global maternal health therapeutics market demonstrated steady growth in 2025, supported by rising government focus on maternal healthcare, increasing investments in women's health programs, and a growing burden of pregnancy-related complications. According to the report, the global maternal health therapeutics market size was valued at USD 4.6 billion in 2025 and is projected to grow from USD 4.91 billion in 2026 to USD 8.84 billion by 2034, registering a CAGR of 7.63% during the forecast period. North America dominated the market with a 42.32% share in 2025, owing to strong healthcare infrastructure, higher institutional births, and greater access to advanced therapeutics.
Maternal health therapeutics include drugs used across preconception, pregnancy, labor & delivery, and postpartum stages to manage complications such as preeclampsia, gestational diabetes, postpartum hemorrhage, and postpartum depression. The rising prevalence of lifestyle-related disorders, delayed pregnancies, and increasing birth complications is driving demand for specialized therapeutic solutions. Additionally, several pharmaceutical companies are strengthening their pipelines to address unmet needs in maternal care.
Market Dynamics
Market Drivers
The rising number of births globally remains a major driver of the maternal health therapeutics market. An increasing maternal population directly expands the risk pool for pregnancy-related complications, driving demand for uterotonics, antihypertensives, insulin, antibiotics, and antidepressants. Growing institutional deliveries and improved access to healthcare services are further supporting market growth.
According to UNICEF (2023), approximately 132.11 billion births were reported globally, highlighting the expanding demand for maternal healthcare services and therapeutics.
Market Restraints
A key restraint is the lack of pregnancy-specific therapeutics. Many drugs used for maternal complications are off-label treatments initially developed for the general population. This reliance raises concerns related to safety, dosage optimization, and long-term outcomes for pregnant and postpartum women.
In December 2023, the World Health Organization (WHO) reported that at least 40.0 million women annually experience long-term health problems caused by childbirth, underscoring the existing treatment gap despite a high disease burden.
Market Opportunities
Innovation in postpartum care offers a major growth opportunity. Postpartum conditions such as hemorrhage, depression, and infections contribute significantly to maternal morbidity and mortality but remain underserved.
In December 2023, Biogen Inc., in collaboration with Sage Therapeutics, launched ZURZUVAE for the treatment of postpartum depression in adults in the U.S., highlighting the growing focus on postpartum therapeutics.
Market Challenges
Limited access to maternal health therapeutics in low-income countries poses a critical challenge. Weak supply chains, inconsistent availability, and poor healthcare infrastructure restrict effective drug distribution.
According to UNICEF (2024), countries such as South Sudan, Chad, and Somalia continue to face inadequate healthcare facilities, limiting access to essential maternal medicines despite growing demand.
Maternal Health Therapeutics Market Trends
An important trend shaping the market is increasing government support for maternal healthcare. Governments are prioritizing maternal safety through national programs, funding initiatives, and policy reforms.
In February 2024, the U.S. Department of Health and Human Services (HHS) launched the Secretary's Postpartum Maternal Health Collaborative to address postpartum mortality, reflecting rising policy-level commitment.
By drug type, fertility drugs are projected to dominate with a 33.39% share in 2026, while hormonal therapies hold a significant share due to high utilization of uterotonics for postpartum hemorrhage. By application, gestational diabetes is projected to lead with a 27.09% share in 2026, while postpartum hemorrhage accounted for 15.7% share in 2025. By phase, preconception is expected to account for 42.25% share in 2026, while the postpartum segment is anticipated to witness strong growth. By route of administration, oral therapies are projected to hold 55.10% share in 2026. By distribution channel, hospital pharmacies dominated with a 50.8% share in 2025, supported by their role in managing high-risk maternal conditions.
North America led the market with USD 1.95 billion in 2025 and USD 2.08 billion in 2026, driven by rising cases of postpartum depression, preeclampsia, and gestational diabetes. Europe reached USD 1.19 billion in 2025, supported by increasing awareness and healthcare investments. Asia Pacific followed with USD 1.14 billion in 2025, while Latin America and the Middle East & Africa recorded USD 0.19 billion and USD 0.06 billion, respectively.
Competitive Landscape
The market is semi-consolidated, with key players such as Johnson & Johnson, Novartis AG, Pfizer Inc., Biogen, and Merck & Co., Inc. focusing on collaborations, R&D investments, and strategic initiatives to expand their maternal health portfolios.
Conclusion
The global maternal health therapeutics market was valued at USD 4.6 billion in 2025 and is expected to grow from USD 4.91 billion in 2026 to USD 8.84 billion by 2034, driven by rising birth rates, increasing maternal complications, strong government support, and expanding pharmaceutical pipelines. North America maintained market leadership, while Europe and Asia Pacific demonstrated significant growth potential. Despite challenges such as limited access in low-income countries and reliance on off-label therapies, continued innovation in postpartum care, supportive government initiatives, and growing awareness of maternal health are expected to sustain market expansion through 2034.
Segmentation By Drug Type, Application, Phase, Route of Administration, Distribution Channel, and Region
By Drug Type * Hormonal Therapies
By Application * Preeclampsia & Gestational Hypertension
By Phase * Preconception
By Route of Administration * Oral
By Distribution Channel * Hospital Pharmacies
By Geography * North America (By Drug Type, Application, Phase, Route of Administration, Distribution Channel, and Country)